Changing SOC: Will New Drugs Pan Out in Pancreatic Cancer?
NEW YORK – Last month's readout of Celgene Corp.'s successful Phase III study testing Abraxane (nab-paclitaxel) in combination with gemcitabine in pancreatic cancer is expected to change the standard of care for patients with metastatic disease, but its modest improvement in overall survival leaves plenty of room for new players in this notoriously difficult therapeutic space – assuming researchers can figure how to attack it.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST